First-Line Combination for Bladder Cancer Not Eligible for Cisplatin Just Misses Positive Outcome.

Published Date: 02 Feb 2024

Out of 35 evaluable patients, 16 showed responses to cabotezantinib-pembrolizumab; one patient was still required.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Coffee, Tea Tied to Lower Risk of Head and Neck Cancer

2.

Research Indicates that First-Line Immunotherapy Is Enough for Elderly NSCLC Patients?

3.

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

4.

Testosterone recovery linked to overall survival in high-risk prostate cancer

5.

Combination therapy improves outcomes for advanced triple-negative breast cancer


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot